摘要
替格瑞洛是新型的P2Y_(12)受体抑制药,其不仅通过抑制P2Y_(12)受体途径,还通过腺苷ENT^(-1)途径发挥作用,展现了其双途径作用机制。同时其不良反应也与双途径作用机制有关。研究显示,替格瑞洛较氯吡格雷的抗血小板作用更强,使急性冠状动脉综合征患者获得较好心血管结果,并且不增加主要心血管事件和猝死率,但在亚洲临床研究尚需更多数据。
Ticagrelor is a new type of P2Y_（12） receptor inhibitor,which not only inhibits P2Y_（12） receptor pathway,but also plays a role through ENT^-1 adenosine pathway,and shows its dual mechanisms. At the same time,its adverse reactions are related to the mechanisms of double pathways. The studies have shown that ticagrelor is more resistant to platelet than clopidogrel,which results in better cardiovascular outcomes in patients with acute coronary syndrome,and does not increase major cardiovascular events and sudden death rate; however,more data are needed in Asian clinical studies.
作者
宋柳全
黎晓亮
何国欢
Song Liuquan;Li Xiaoliang;He Guohuan(Department of Pharmacy;Department of Cardiology, Wuzhou Gongren Hospital of Guangxi Province, Guangxi Wuzhou 543001, China)
出处
《中国药师》
CAS
2018年第7期1269-1274,共6页
China Pharmacist
关键词
替格瑞洛
抗血小板作用
双途经
临床应用
Ticagrelor
Anti-platelet function
Dual pathway mechanism
Clinical application
